Evidence map›Paper›PMID 41026304›Full record

ArticleMikrochimica acta2025

Enzyme-free quantification of breast cancer-derived exosomes via cubic DNA nanostructure-enhanced hybridization chain reaction.

Wenting Cheng, Jinhua Chen, Han Pan, Miao He, Yongliang Cai, Zhongyun Wang, Yang Xiang

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenting ChengState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, People's Republic of China.
Jinhua ChenState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, People's Republic of China.
Han PanState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, People's Republic of China.
Miao HeState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, People's Republic of China.
Yongliang CaiDepartment of Anesthesiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Zhongyun WangDepartment of Anesthesiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. zywang1970@126.com.
Yang XiangState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, People's Republic of China. xiangy@nju.edu.cn.

Funding

National Natural Science Foundation of China 81672570National Natural Science Foundation of China 82371283Natural Science Foundation of Jiangsu Province of China BK20240264State Key Laboratory of Natural and Biomimetic Drugs K202009
6 · The paper itself

Abstract

Breast tumor-derived exosomes promise to guide diagnosis and therapy. But the small size and low mass of exosomes have higher requirements for target binding and signal amplification. Although hybridization chain reaction (HCR) has been extensively utilized for the sensitive detection of an enormous range of biomolecules, including the exosomes, achieving sufficient amplification efficiency remains challenging. To address this limitation, more and more researchers integrate the reaction system with functional materials of DNA. Inspired by this, we herein report for the first time the cubic DNA nanostructure enhanced hybridization chain reaction (CDN-HCR) to detect breast tumor-derived exosomes. Unlike other nanostructure-assisted HCR approaches, the four cholesterol anchors on the CDN enhance the binding affinity of signal probes for exosomes, while the four triggers combined with the supporting CDN further improve the reaction efficiency of HCR. Furthermore, incorporating an electrochemical detection system, the assay platform enables enzyme-free and label-free detection of exosomes. The quantitative detection of exosomes is easily achieved with a linear range of 5.5 × 10

Indexed as

Breast NeoplasmsDNAExosomesNanostructuresNucleic Acid HybridizationBiosensing TechniquesElectrochemical TechniquesFemaleHumansLimit of DetectionMicroRNAsDNAMicroRNAsBreast cancer–derived exosomesCubic DNA nanostructureDifferential pulse voltammetryElectroanalysisHCR

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.